全文获取类型
收费全文 | 48044篇 |
免费 | 2422篇 |
国内免费 | 389篇 |
专业分类
耳鼻咽喉 | 504篇 |
儿科学 | 881篇 |
妇产科学 | 1407篇 |
基础医学 | 5731篇 |
口腔科学 | 2038篇 |
临床医学 | 3701篇 |
内科学 | 13242篇 |
皮肤病学 | 995篇 |
神经病学 | 4166篇 |
特种医学 | 1376篇 |
外科学 | 7096篇 |
综合类 | 189篇 |
一般理论 | 12篇 |
预防医学 | 2727篇 |
眼科学 | 753篇 |
药学 | 2708篇 |
中国医学 | 131篇 |
肿瘤学 | 3198篇 |
出版年
2024年 | 44篇 |
2023年 | 345篇 |
2022年 | 827篇 |
2021年 | 1561篇 |
2020年 | 853篇 |
2019年 | 1213篇 |
2018年 | 1657篇 |
2017年 | 1107篇 |
2016年 | 1190篇 |
2015年 | 1404篇 |
2014年 | 1914篇 |
2013年 | 2523篇 |
2012年 | 3811篇 |
2011年 | 3808篇 |
2010年 | 2152篇 |
2009年 | 1861篇 |
2008年 | 3205篇 |
2007年 | 3324篇 |
2006年 | 3082篇 |
2005年 | 3046篇 |
2004年 | 2737篇 |
2003年 | 2450篇 |
2002年 | 2151篇 |
2001年 | 336篇 |
2000年 | 236篇 |
1999年 | 350篇 |
1998年 | 423篇 |
1997年 | 356篇 |
1996年 | 313篇 |
1995年 | 303篇 |
1994年 | 247篇 |
1993年 | 182篇 |
1992年 | 162篇 |
1991年 | 127篇 |
1990年 | 139篇 |
1989年 | 124篇 |
1988年 | 109篇 |
1987年 | 77篇 |
1986年 | 106篇 |
1985年 | 91篇 |
1984年 | 100篇 |
1983年 | 85篇 |
1982年 | 107篇 |
1981年 | 76篇 |
1980年 | 85篇 |
1979年 | 47篇 |
1978年 | 54篇 |
1977年 | 46篇 |
1976年 | 46篇 |
1974年 | 35篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction 总被引:11,自引:0,他引:11
Marenzi G Lauri G Assanelli E Campodonico J De Metrio M Marana I Grazi M Veglia F Bartorelli AL 《Journal of the American College of Cardiology》2004,44(9):1780-1785
OBJECTIVES: The aim of this research was to assess the incidence, clinical predictors, and outcome of contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). BACKGROUND: Contrast-induced nephropathy is associated with significant morbidity and mortality after PCI. Patients undergoing primary PCI may be at higher risk of CIN because of hemodynamic instability and unfeasibility of adequate prophylaxis. METHODS: In 208 consecutive AMI patients undergoing primary PCI, we measured serum creatinine concentration (Cr) at baseline and each day for the following three days. Contrast-induced nephropathy was defined as a rise in Cr >0.5 mg/dl. RESULTS: Overall, CIN occurred in 40 (19%) patients. Of the 160 patients with baseline Cr clearance >/=60 ml/min, only 21 (13%) developed CIN, whereas it occurred in 19 (40%) of those with Cr clearance <60 ml/min (p < 0.0001). In multivariate analysis, age >75 years (odds ratio [OR] 5.28, 95% confidence interval [CI] 1.98 to 14.05; p = 0.0009), anterior infarction (OR 2.17, 95% CI 0.88 to 5.34; p = 0.09), time-to-reperfusion >6 h (OR 2.51, 95% CI 1.01 to 6.16; p = 0.04), contrast agent volume >300 ml (OR 2.80, 95% CI 1.17 to 6.68; p = 0.02) and use of intraaortic balloon (OR 15.51, 95% CI 4.65 to 51.64; p < 0.0001) were independent correlates of CIN. Patients developing CIN had longer hospital stay (13 +/- 7 days vs. 8 +/- 3 days; p < 0.001), more complicated clinical course, and significantly higher mortality rate (31% vs. 0.6%; p < 0.001). CONCLUSIONS: Contrast-induced nephropathy frequently complicates primary PCI, even in patients with normal renal function. It is associated with higher in-hospital complication rate and mortality. Thus, preventive strategies are needed, particularly in high-risk patients. 相似文献
992.
Since their introduction into clinical practice, somatostatin analogs have been the pharmacological therapy of choice for the treatment of acromegaly. The first preparations of somatostatin analogs available for clinical use were administered subcutaneously two or three times daily, which was not optimal with respect to patient compliance. The introduction of long-acting formulations of somatostatin analogs has overcome this inconvenience. Lanreotide Autogel, a new viscous, supersaturated, aqueous solution of lanreotide, is available in a prefilled syringe and administered by deep subcutaneous injection every 28 days. Lanreotide Autogel has different pharmacokinetic properties from the earlier lanreotide slow-release (SR) formulation, which may account for its better tolerability. Furthermore, lanreotide Autogel is at least as efficacious as the other somatostatin analogs in lowering growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels in the majority and in restoring safe GH and age-normalized IGF-1 levels in about 50-60% of patients with acromegaly. In conclusion, lanreotide Autogel is a valuable new addition to the acromegaly treatment armamentarium. Patients receiving intramuscular lanreotide SR injections every 7-14 days can be switched to an appropriate dose of deep subcutaneous lanreotide Autogel every 28 days, without any impact on safety or loss of efficacy. 相似文献
993.
Thyroid hormones influence gene expression in virtually all vertebrate tissues. Precise regulation of the active endogenous ligand, 3,5,3'-triiodothyronine (T(3)), is achieved by the sequential removal of iodine moieties from the thyroid hormone molecule. Type III iodothyronine deiodinase (D3) is the major inactivating enzyme terminating the action of T(3) and preventing activation of the prohormone, thyroxine (T(4)). Recent studies have revealed the induction of high D3 activity in diverse animal models of tissue injury including starvation, cryolesion, cardiac hypertrophy, infarction, and chronic inflammation. By analyzing serum and tissues taken from hospitalized patients at the time of death, investigators have also documented the robust induction of D3 activity in several human tissues that normally have none, including the liver and skeletal muscle, and shown clinically relevant consequences to systemic thyroid status. These studies reveal a novel role of D3 in the tissue response to injury and in the derangement of thyroid hormone homeostasis commonly observed during critical illness. 相似文献
994.
Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man 总被引:6,自引:0,他引:6
M L Vance J L Borges D L Kaiser W S Evans R Furlanetto J L Thominet L A Frohman A D Rogol R M MacLeod S Bloom 《The Journal of clinical endocrinology and metabolism》1984,58(5):838-844
Human pancreatic GRF (hpGRF-40; 1 microgram/kg, iv) selectively stimulates GH release in normal men (9). We now report the effects of graded doses of hpGRF-40 on GH release in 12 normal men. Mean peak increments in serum GH after vehicle and the various doses of hpGRF-40 were 1.13, 11.40, 14.60, 17.01, 14.45, and 15.60 ng/ml after vehicle and 0.1, 0.33, 1.0, 3.3, and 10 micrograms/kg hpGRF-40 (iv bolus), respectively. Peak values were observed 30-60 min after hpGRF-40 treatment. There was considerable variability of responsiveness among individual subjects, and no dose-response relationship between the doses and maximal GH values was found. However, the higher doses of 3.3 and 10.0 micrograms/kg resulted in a more prolonged and biphasic pattern of GH release. A side effect of facial flushing of less than 5-min duration occurred in 4 or 6 subjects who received 3.3 micrograms/kg and in all 5 who received 10 micrograms/kg of hpGRF-40. No changes in serum glucose, LH, TSH, PRL, plasma cortisol, or 8 enteropancreatic hormones occurred after hpGRF-40 treatment. There were small increases in serum somatomedin C levels 24 h after the administration of various doses of hpGRF-40 in 11 of 13 studies. Plasma immunoreactive GRF levels measured 5 min after injection were 0.09, 2.0, 4.9, 23.9, and 66.6 ng/ml after 0.1, 0.33, 1.0, 3.3, and 10 micrograms/kg hpGRF-40, respectively. Serum GH responses after insulin-induced hypoglycemia were compared to GH responses after hpGRF-40. Comparable peak GH stimulation occurred with both provocative tests. Mean +/- SEM peak GH was 20.2 +/- 1.0 ng/ml after insulin and 20.9 +/- 3.2 after hpGRF-40 treatment. hpGRF-40 selectively stimulates GH release in normal men over a dose range of 0.1-10 micrograms/kg and is an effective probe to investigate the dynamics of GH release. 相似文献
995.
GianCarlo Marenzi Antonio L Bartorelli Gianfranco Lauri Emilio Assanelli Marco Grazi Jeness Campodonico Ivana Marana 《Catheterization and cardiovascular interventions》2003,58(1):59-64
Acute renal failure (ARF) requiring hemodialysis after percutaneous coronary interventions (PCI) is a serious complication with poor prognosis. Hemodialysis-induced hypotension may have deleterious cardiovascular effects, especially in high-risk patients. Ultrafiltrate removal and simultaneous fluid replacement with a solution similar to plasma for high-volume controlled hydration can be obtained with hemodynamic stability by continuous veno-venous hemofiltration (CVVH). We prospectively assessed the safety and effectiveness of percutaneous CVVH (Y-shaped double-lumen catheter, circuit originating from and terminating in the femoral vein) in 33 consecutive patients (23 men and 10 women; mean age, 69 +/- 9 years) who, after PCI, developed oligo-anuric ARF, associated in 20 of them with congestive heart failure. All patients received a concomitant infusion of furosemide (500-1000 mg/day) and dopamine (2 microg/kg/min). During CVVH, the average fluid volume replacement and body fluid net reduction were 1000 +/- 247 and 75 +/- 48 ml/hr, respectively. Treatment with CVVH continued for 4.7 +/- 2.7 days and corrected fluid overload in all cases. No patient experienced systemic hypotension or hypovolemia. Diuresis recovered in 32 (97%) patients, who showed a parallel improvement of renal function parameters. One patient required chronic dialysis. In-hospital and 1-year mortality was 9.1% and 27.3%, respectively. In conclusion, our data indicate that CVVH is a safe and effective therapy of radiocontrast-induced ARF following PCI. It temporarily replaces renal function without deleterious cardiovascular effects, allowing the kidney to recover from the nephrotoxic injury. However, despite promising early results, large randomized trials are required to define the role of CVVH in ARF after PCI. 相似文献
996.
The open-artery hypothesis states that myocardial reperfusion, even if late for myocardial salvage, provides benefits and prevents adverse cardiac remodeling. While observational data in humans regarding the deleterious impact of a permanent infarct-related artery occlusion and the benefits of spontaneous reperfusion are quite consistent, the reports regarding late revascularization are inconclusive in order to prove such a hypothesis. The observational studies tend to have selection biases, while randomized trials to date are too small to be conclusive. Moreover, the pathophysiological mechanisms underlying presumed benefits of reperfusion are still unclear. However, although the open-artery hypothesis remains unproven, the current evidence suggesting benefits calls for additional studies. Limitations of ischemic left ventricular dilatation and myopathy could markedly reduce cardiovascular morbidity and mortality after acute myocardial infarction. 相似文献
997.
998.
Piero Barbanti MD PhD Luisa Fofi MD Licia Grazzi MD Fabrizio Vernieri MD Cecilia Camarda MD Paola Torelli MD Sabina Cevoli MD PhD Antonio Russo MD PhD Francesco Bono MD Cinzia Finocchi MD Renata Rao MD Stefano Messina MD Roberto De Simone MD Nicola Vanacore MD PhD Stefano Bonassi PhD ERT IRON Study Group 《Headache》2021,61(6):936-950
999.
Piero Barbanti MD PhD Cinzia Aurilia MD Sabina Cevoli MD PhD Gabriella Egeo MD PhD Luisa Fofi MD Roberta Messina MD Antonio Salerno MD Paola Torelli MD Maria Albanese MD PhD Antonio Carnevale MD Francesco Bono MD Domenico D'Amico MD Massimo Filippi MD Claudia Altamura MD PhD Fabrizio Vernieri MD EARLY Study Group 《Headache》2021,61(9):1351-1363
1000.
Juan Ramn Tejedor Clara Bueno Meritxell Vinyoles Paolo Petazzi Antonio Agraz-Doblas Isabel Cobo Raúl Torres-Ruiz Gustavo F. Bayn Raúl F. Prez Sara Lpez-Tamargo Francisco Gutierrez-Agüera Pablo Santamarina-Ojeda Manuel Ramírez-Orellana Michela Bardini Giovanni Cazzaniga Paola Ballerini Pauline Schneider Ronald W. Stam Ignacio Varela Mario F. Fraga Agustín F. Fernndez Pablo Menndez 《The Journal of clinical investigation》2021,131(13)